On Wednesday, Shares of Regions Financial Corp (NYSE:RF), gain 0.34% to $8.95.
Regions Financial is planned to release its third quarter 2015 financial results on Tuesday, October 20, 2015. Executives from the company will review Regions’ third quarter results via teleconference and live audio webcast starting at 11 a.m. ET.
Regions Financial Corporation is a financial holding company. The Company conducts its banking operations through Regions Bank, an Alabama state-chartered commercial bank, which is a member of the Federal Reserve System. The Company carries out its business in three segments: Corporate Bank, Consumer Bank and Wealth Administration. The Corporate Bank segment represents the Company’s commercial banking functions, counting commercial and industrial, commercial real estate and investor real estate lending.
Shares of Itau Unibanco Holding SA (ADR) (NYSE:ITUB), declined -5.56% to $6.36, during its last trading session, after the Brazilian real fell to an all-time low of 4.12 per dollar as the country contends with political and economic turmoil.
On Wednesday, Brazil’s Congress voted to uphold some presidential vetoes, but postponed a vote on a bill that would raise judiciary workers’ salary and cost the government 47 billion reais ($11.5 billion) through 2019, The Wall Street Journal reports.
Investors worry that lawmakers’ possible rejection of the veto against the salary improvement would interfere with President Dilma Rousseff’s efforts to close the 2016 budget deficit, according to Reuters. The S&P downgraded Brazil’s sovereign rating to junk earlier this month because of the budget gap.
Itau Unibanco Holding S.A. (Itau Unibanco Holding) is a holding company. The Company provides a range of financial products and services to individual and corporate clients in Brazil. It operates in four segments: Commercial Bank-Retail, which offers a range of banking services for retail individuals or clients and for companies, counting services, such as asset administration, investor services, insurance, private pension plans and credit cards issued to account holders; Consumer Credit-Retail, which offers financial products and services to account holders, such as vehicle financing, credit card transactions and consumer financing; Wholesale Bank, which offers wholesale products and services to large and medium-sized companies, in addition to investment bank activities and The Activities with the Market and Corporation segment manages the interest income associated with ITAU UNIBANCO HOLDING capital surplus, subordinated debt surplus and the net balance of tax credits and debits.
Shares of United Technologies Corporation (NYSE:UTX), declined -1.41% to $86.96, during its last trading session.
Otis Elevator has launched the next generation of its industry-leading eService, a responsive customer platform that proactively provides elevator, escalator and moving walkway maintenance information in real-time via computer, tablet or smart phone devices. With nearly 2 million units covered by Otis service agreements, the redesigned eService is now available to support one of the most extensive service networks in the world. eService can be accessed by all customers with equipment covered by Otis service contracts, counting non-Otis equipment. Otis is a unit of United Technologies Corp. (UTX).
The eService communication system pushes real-time vital information to customers online, in addition to through e-mail and text messages to keep them up-to-date on equipment performance, service requests, maintenance activities and critical account information. Through one simple performance dashboard, Otis customers can review elevator service history and performance data, place a service call, receive instantaneous pop-up alerts on issues and open calls, review contracts and other important service documents, manage proposals, check and pay invoices, preview the latest upgrades, book an appointment, contact Otis and more, with available features depending on location.
United Technologies Corporation (UTC) provides high technology products and services to the building systems and aerospace industries across the world. The Company operates through five segments: Otis; UTC Climate, Controls & Security; Pratt & Whitney; UTC Aerospace Systems and Sikorsky.
Finally, Conatus Pharmaceuticals Inc (NASDAQ:CNAT), ended its last trade with 5.74% gain, and closed at $5.74.
Conatus Pharmaceuticals declared that the company’s exploratory Phase 2 Portal Hypertension (PH) clinical trial of emricasan, a first-in-class, orally active pan-caspase inhibitor, met the following primary endpoints: a) a clinically meaningful and statistically noteworthy change from baseline in hepatic venous pressure gradient (HVPG), a measurement of pressure in the portal vein, in patients with liver cirrhosis and severe portal hypertension (HVPG >=12 mmHg); and b) a statistically noteworthy change from baseline in cleaved Cytokeratin 18 (cCK18), a mechanism-specific biomarker of excessive cell death that contributes to chronic inflammation, in the total evaluable liver cirrhosis patient population.
The open-label PH trial was conducted at nine U.S. sites and enrolled 23 patients (22 evaluable) with portal hypertension and compensated liver cirrhosis that was predominantly due to nonalcoholic steatohepatitis (NASH) or hepatitis C virus (HCV), counting patients with active HCV infection and patients who had a sustained viral response (SVR) to antiviral therapy. Portal hypertension, or elevated blood pressure in the major vein feeding into the liver, was confirmed by HVPG measurement >5 mmHg at baseline and measured again after treatment with 25 mg of emricasan orally twice daily for 28 days. Patients were divided according to the HVPG therapeutic threshold of 12 mmHg, which indicates more severe portal hypertension. Reducing the HVPG to below 12 mmHg or reducing HVPG by >=10% or >=20% has been strongly associated with clinical benefit in this patient population.
Conatus Pharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of medicines to treat liver disease. The Company’s lead compound, emricasan, is an orally active pan-caspase protease inhibitor designed to reduce the activity of human caspases, which are enzymes that mediate inflammation and apoptosis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
